Resources Repository
-
GuidelinesPublication 2016Estimating Health-State Utility for Economic Models: ISPOR Task Force Report
Cost-utility models are increasingly used in many countries to establish whether the cost of a …
Cost-utility models are increasingly used in many countries to establish whether the cost of a new intervention can be justified in terms of health benefits. Health-state utility (HSU) estimates (the preference for a given state of health on a cardinal scale where 0 represents dead and 1 represents full health) are typically among the most important and uncertain data inputs in cost-utility models. Clinical trials represent an important opportunity for the collection of health-utility data.…
Preferences/Values | Mathematical Models | Technology Assessment | Health Systems | Health Outcomes | Cost-Effectiveness Analysis | Health/Medicine | Science/Technology | North America | Europe -
ReviewPublication 2016Choosing an Epidemiological Model Structure for Economic Evaluation
This review presents a taxonomy of epidemiological model structures and applies it to the economic …
This review presents a taxonomy of epidemiological model structures and applies it to the economic evaluation of public health interventions for non-communicable diseases. Growing pressures on health services and on social care have led to a greater need for prevention of chronic diseases. In order for decision makers to make informed judgements about how to best spend finite public health resources, they must be able to quantify the anticipated costs, benefits, and opportunity costs of…
Mathematical Models | Dynamic Transmission | Health Systems | State-Transition | Microsimulation | Dynamic Simulation | Chronic Disease/Risk | Social Determinants | Environmental Health | Climate/Environment | Culture/Society | Health/Medicine -
ReportPublication 2015Opioid Dependence: Final Report
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value …
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value of interventions for the management of opioid dependence. The goals of the report are to document the federal and New England state regulations affecting treatment options, provide an overview of existing clinical guidelines and payer coverage policies, and summarize the evidence on the different management approaches for opioid dependence, including special considerations for adolescents. An appendix is provided by ICER.…
Preferences/Values | Technology Assessment | Health Systems | Health Outcomes | Evidence Synthesis | Cost-Effectiveness Analysis | Chronic Disease/Risk | Mental Health | Policy/Regulation | Business/Industry | Government/Law | Health/Medicine | Science/Technology | North America -
ReviewPublication 2001Modeling for Health Care and Other Policy Decisions: Uses, Roles and Validity
This is a review article of the role of modeling approaches to guide decision making …
This is a review article of the role of modeling approaches to guide decision making in health care and other domains. The role of models to support recommendations on the cost-effective use of medical technologies and pharmaceuticals is controversial. At the heart of the controversy is the degree to which experimental or other empirical evidence should be required prior to model use. The authors argue that the controversy stems in part from a misconception that…
Mathematical Models | Technology Assessment | Health Systems | Priority Setting/Ethics | Evidence Synthesis | Environmental Health | Policy/Regulation | Business/Industry | Climate/Environment | Economics/Finance | Energy/Engineering | Government/Law | Health/Medicine | North America -
EditorialPublication 2020Waiting for Certainty on COVID-19 Antibody Tests — At What Cost?
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation …
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation policy to reduce COVID-19 transmission. For example: Could we screen for serologic antibodies as a proxy for possible immunity and identify people who could return to the workplace with less severe mitigation measures? The authors acknowledge the uncertainties raised by many policy actors, including the WHO, such as, "Do antibodies confer immunity and, if so, for how long? How accurate is…
Technology Assessment | Health Systems | Probability/Bayes | Test Performance | Infectious Diseases | Policy/Regulation | Government/Law | Health/Medicine | Global | North America -
ReportPublication 2010Priorities for the National Vaccine Plan
The authors examine the complexities of the vaccine enterprise, a fundamental component of preventive medicine …
The authors examine the complexities of the vaccine enterprise, a fundamental component of preventive medicine and public health, from research and development of new vaccines to financing and reimbursement of immunization services. The current climate, socially, economically and politically, presents challenges and opportunities to the U.S. to strengthen the existing systems of developing, manufacturing, regulating, distributing, funding, and administering safe and effective vaccines for all people. The authors present recommendations for priority actions intended to…
Technology Assessment | Health Systems | Evidence Synthesis | Infectious Diseases | Chronic Disease/Risk | Policy/Regulation | Economics/Finance | Health/Medicine | Science/Technology | North America -
ReportPublication 2013Decision and Simulation Modeling Alongside Systematic Reviews
This chapter is part of a report entitled, Decision and Simulation Modeling in Systematic Reviews, that seeks …
This chapter is part of a report entitled, Decision and Simulation Modeling in Systematic Reviews, that seeks to provide guidance for determining when incorporating a decision-analytic model alongside a systemic review would be of added value for decision making purposes. The chapter discusses the role of decision analysis and decision-analytic models in health care, specifically within the context of the current emphasis on evidence-based medicine and the proliferation of systematic reviews. It describes the types of model available…
Dynamic Transmission | Health Systems | Evidence Synthesis | State-Transition | Microsimulation | Dynamic Simulation | Clinical Care | Health/Medicine -
ReviewPublication 2018Patient Variability Seldom Assessed in Cost-Effectiveness Studies
This article in Medical Decision Making reviews 200 articles published in 2014 to determine whether …
This article in Medical Decision Making reviews 200 articles published in 2014 to determine whether each cost-effectiveness analysis (CEA) study reported subgroup results and collected data on the defining characteristics of these subgroups. Since estimates can vary across patient subgroups when characteristics are influenced by preferences, outcome risks, treatment effectiveness, life expectancy, or associated costs it can be important to track and report these differences. The authors identified whether any of the CEA subgroup results…
Preferences/Values | Health Systems | Cost-Effectiveness Analysis | Social Determinants | Policy/Regulation | Health/Medicine | Global -
ReviewPublication 2017Patients' Preferences in Cancer Treatment: Review of Discrete Choice Experiments
This study aimed to systematically review discrete choice experiments (DCEs) about patients’ preferences for cancer …
This study aimed to systematically review discrete choice experiments (DCEs) about patients’ preferences for cancer treatment and assessed the relative importance of outcome, process and cost attributes. A systematic literature review was conducted using PubMed and EMBASE to identify all DCEs investigating patients’ preferences for cancer treatment between January 2010 and April 2016. Attributes were classified into outcome, process and cost attributes, and their relative importance was assessed. A total of 28 DCEs were identified.…
Preferences/Values | Health Systems | Health Outcomes | Decision Analysis | Cost-Effectiveness Analysis | Chronic Disease/Risk | Economics/Finance | Health/Medicine | North America | Europe